SE405601B - Forfarande for framstellning av 1-(3-(naft-1-yl-oxi)-2-hydroxipropyl)-piperazinderivat - Google Patents

Forfarande for framstellning av 1-(3-(naft-1-yl-oxi)-2-hydroxipropyl)-piperazinderivat

Info

Publication number
SE405601B
SE405601B SE7501911A SE7501911A SE405601B SE 405601 B SE405601 B SE 405601B SE 7501911 A SE7501911 A SE 7501911A SE 7501911 A SE7501911 A SE 7501911A SE 405601 B SE405601 B SE 405601B
Authority
SE
Sweden
Prior art keywords
hydroxipropyl
naft
oxi
preparing
procedure
Prior art date
Application number
SE7501911A
Other languages
English (en)
Swedish (sv)
Other versions
SE7501911L (fr
Inventor
E-C Witte
K Stach
M Thiel
G Sponer
E Roesch
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of SE7501911L publication Critical patent/SE7501911L/xx
Publication of SE405601B publication Critical patent/SE405601B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7501911A 1974-02-23 1975-02-20 Forfarande for framstellning av 1-(3-(naft-1-yl-oxi)-2-hydroxipropyl)-piperazinderivat SE405601B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2408804A DE2408804C2 (de) 1974-02-23 1974-02-23 1-(2-Methoxyphenyl)-4-[3-(naphth-1-yl-oxy)-2-hydroxy-propyl]-piperazin, dessen Salze, Verfahren zu ihrer Herstellung sowie Arzneimittel, die diese Verbindungen enthalten

Publications (2)

Publication Number Publication Date
SE7501911L SE7501911L (fr) 1975-08-25
SE405601B true SE405601B (sv) 1978-12-18

Family

ID=5908286

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7501911A SE405601B (sv) 1974-02-23 1975-02-20 Forfarande for framstellning av 1-(3-(naft-1-yl-oxi)-2-hydroxipropyl)-piperazinderivat

Country Status (20)

Country Link
US (1) US3997666A (fr)
JP (1) JPS6029712B2 (fr)
AR (1) AR206339A1 (fr)
AT (1) AT340937B (fr)
BE (1) BE825755A (fr)
CA (1) CA1039282A (fr)
CH (2) CH609342A5 (fr)
DE (1) DE2408804C2 (fr)
DK (1) DK135124C (fr)
ES (1) ES434829A1 (fr)
FI (1) FI59248C (fr)
FR (1) FR2261770B1 (fr)
GB (1) GB1445548A (fr)
IE (1) IE40678B1 (fr)
NL (2) NL175059B (fr)
PL (1) PL92131B1 (fr)
SE (1) SE405601B (fr)
SU (2) SU549085A3 (fr)
YU (2) YU37156B (fr)
ZA (1) ZA751031B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2387971A1 (fr) * 1977-04-19 1978-11-17 Delalande Sa Nouvelles trimethoxy cinnamoyles piperazines, leur procede de preparation et leur application en therapeutique
US4882330A (en) * 1986-11-21 1989-11-21 A. H. Robins Company, Incorporated 1-aryloxy-4-[((4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents
EP0269383A3 (fr) * 1986-11-21 1990-05-02 A.H. Robins Company, Incorporated 1-Aryloxy-4-[(4-aryl)-1-pipérazinyl]-2-butanols utiles pour traiter des manifestations allergiques
DE3918543A1 (de) * 1989-06-07 1990-12-13 Boehringer Mannheim Gmbh Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
DE3918542A1 (de) * 1989-06-07 1990-12-13 Boehringer Mannheim Gmbh Hydroxylierte 1-phenyl-4-(3-(napthth-1-yl-oxy)-2-hydroxy -propyl)-piperazine, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
CA2278660A1 (fr) 1997-01-30 1998-08-06 Kazumi Ogata Derives d'hydroquinone
CN1572299A (zh) 1998-09-30 2005-02-02 武田药品工业株式会社 改善膀胱排泄能力的药物
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (fr) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
NZ543741A (en) 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
ATE412648T1 (de) 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2009504628A (ja) * 2005-08-10 2009-02-05 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP5483880B2 (ja) * 2006-10-23 2014-05-07 武田薬品工業株式会社 イミノピリジン誘導体およびその用途
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US20110039892A1 (en) 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
CN101671317B (zh) * 2009-10-09 2011-04-27 蚌埠丰原涂山制药有限公司 一种萘哌地尔的制备方法
CN101747293B (zh) * 2009-12-29 2011-12-07 蚌埠丰原涂山制药有限公司 萘哌地尔的制备方法
JP5807423B2 (ja) * 2011-07-21 2015-11-10 大日本印刷株式会社 ナフトピジルの製造方法
CN102816136A (zh) * 2012-09-18 2012-12-12 通化吉通药业有限公司 萘哌地尔制备方法
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
US9272980B2 (en) 2014-06-06 2016-03-01 Ktn Biotec, Inc. Anticancer agent
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
JP7128969B2 (ja) 2019-01-18 2022-08-31 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA967965A (en) * 1968-12-24 1975-05-20 Hoffmann-La Roche Limited Aromatic ethers and process for the manufacture thereof
GB1317479A (en) * 1970-11-10 1973-05-16 Pfizer Ltd 1-2-hydroxy-3-phenoxy or phenylthiopropyl-4-phenyl-piperazine derivatives
DE2235597A1 (de) * 1972-07-20 1974-01-31 Boehringer Mannheim Gmbh 1-eckige klammer auf 3-(5,6,7,8tetrahydronaphth-1-yl-oxy) -propyl eckige klammer zu -piperazin-derivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
SU549085A3 (ru) 1977-02-28
ZA751031B (en) 1976-02-25
IE40678L (en) 1975-08-23
NL175059C (nl)
YU38275A (en) 1983-04-27
DE2408804C2 (de) 1983-09-22
CH612958A5 (fr) 1979-08-31
JPS6029712B2 (ja) 1985-07-12
IE40678B1 (en) 1979-08-01
YU37157B (en) 1984-08-31
SE7501911L (fr) 1975-08-25
BE825755A (fr) 1975-08-20
FI750449A (fr) 1975-08-24
NL7501877A (nl) 1975-08-26
DK135124B (da) 1977-03-07
ATA132375A (de) 1977-05-15
YU104481A (en) 1983-04-27
DE2408804A1 (de) 1975-09-04
ES434829A1 (es) 1976-12-01
US3997666A (en) 1976-12-14
FR2261770A1 (fr) 1975-09-19
YU37156B (en) 1984-08-31
FI59248B (fi) 1981-03-31
FR2261770B1 (fr) 1978-08-04
DK58175A (fr) 1975-10-20
GB1445548A (en) 1976-08-11
AR206339A1 (es) 1976-07-15
CA1039282A (fr) 1978-09-26
FI59248C (fi) 1981-07-10
CH609342A5 (fr) 1979-02-28
NL175059B (nl) 1984-04-16
AT340937B (de) 1978-01-10
DK135124C (da) 1977-08-15
SU561514A3 (ru) 1977-06-05
JPS50121286A (fr) 1975-09-23
PL92131B1 (fr) 1977-03-31
AU7826875A (en) 1976-08-19

Similar Documents

Publication Publication Date Title
SE405601B (sv) Forfarande for framstellning av 1-(3-(naft-1-yl-oxi)-2-hydroxipropyl)-piperazinderivat
SE428562B (sv) Forfarande for framstellning av purinderivat
SE420199B (sv) Forfarande for framstellning av 16-oxiderade prostansyraderivat
SE416299B (sv) Forfarande for framstellning av heterocykliska foreningar
SE423633B (sv) Forfarande for framstellning av 4-demetoxi-daunomycin
SE420727B (sv) Analogiforfarande for framstellning av bispidin- och bispidonderivat
SE431652B (sv) Forfarande for framstellning av 7beta-amino-3cefem-3ol-4-karboxylsyraderivat
SE412066B (sv) Forfarande for framstellning av famakologiskt verksamma tienodiazinderivat
SE431211B (sv) Forfarande for framstellning av n-acylamino-alfa-arylacetamido-cefalosporiner
SE417533B (sv) Forfarande for limning av papper
SE7508074L (sv) Forfarande for framstellning av stilbenderivat.
SE421612B (sv) Forfarande for framstellning av alfa-6-deoxi-5-hydroxitetracyklin
SE422052B (sv) Forfarande for framstellning av vissa angivna 1-fenoxi-2-hydroxi-3-aminofenyl-propylderivat
SE418292B (sv) Forfarande for framstellning av 5-aryl-2-furamidiner
AR213287A1 (es) Procedimiento para preparar derivados de 4-(2-hidroxi-3-aminopropoxi)-indol
SE425739B (sv) Forfarande for framstellning av vissa angivna tetrazolyl-bensopyranopyridinderivat
SE422202B (sv) Forfarande for framstellning av amidoximderivat
SE422210B (sv) Analogiforfarande for framstellning av substituerade indoler
SE414926B (sv) Forfarande for framstellning av 1-alkyl-2-(fenoximetyl)-5-nitroimidazoler
SE415658B (sv) Analogiforfarande for framstellning av linnolinderivat
SE404364B (sv) Forfarande for framstellning av vissa angivna 5-sulfonylfenyl-tetrazolderivat
SE425784B (sv) Analogiforfarande for framstellning av eburnameninderivat
SE405600B (sv) Forfarande for framstellning av 1-(3-(naft-1-yl-oxi)-propyl)-piperazinderivat
SE421310B (sv) Forfarande for framstellning av substituerade bensoylpyridiner
SE430162B (sv) Nytt forfarande for framstellning av cefalosporinderivat

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7501911-7

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7501911-7

Format of ref document f/p: F